SUNScholar will be offline for maintenance from 10:00 SAST on Wednesday the 21st of November 2018.

ITEM VIEW

Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: A meta-analysis of randomized controlled trials

dc.contributor.authorStein D.J.
dc.contributor.authorSeedat S.
dc.contributor.authorVan der Linden G.J.H.
dc.contributor.authorZungu-Dirwayi N.
dc.date.accessioned2011-05-15T15:59:19Z
dc.date.available2011-05-15T15:59:19Z
dc.date.issued2000
dc.identifier.citationInternational Clinical Psychopharmacology
dc.identifier.citation15
dc.identifier.citationSUPPL. 2
dc.identifier.issn2681315
dc.identifier.urihttp://hdl.handle.net/10019.1/11112
dc.description.abstractAdvances in the neurobiology of post-traumatic stress disorder (PTSD) and the availability of modern psychotropics have led to renewed interest in the pharmacotherapy of this disorder. In this paper we focus on trials of the selective serotonin reuptake inhibitors (SSRIs) in PTSD. Studies of the pharmacotherapy of PTSD were identified using methods developed by the Cochrane collaboration. Although a range of open trials of different SSRIs in PTSD show promise, there are few controlled pharmacotherapy studies in this disorder. Nevertheless, pharmacotherapy for PTSD appears to have reasonably robust effects, with odds ratios for responder status, defined as 'much improved' or 'very much improved' on the Clinical Global Impression Scale (CGI), on drug versus placebo varying from 2.2 to 5.6 in randomized controlled trials of different agents. The SSRIs appear both safe and effective for this indication. Additional research with these agents is necessary to clarify many questions, including predictors of response, duration of treatment, comparison with other agents, and integration with psychotherapy. In the interim, however, the SSRIs can be recommended as a first-line medication for the treatment of PTSD. (C) 2000 Lippincott Williams and Wilkins.
dc.subjectplacebo
dc.subjectserotonin uptake inhibitor
dc.subjectclinical trial
dc.subjectconference paper
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjecthuman
dc.subjectmeta analysis
dc.subjectneurobiology
dc.subjectneuroendocrine disease
dc.subjectneurotransmission
dc.subjectposttraumatic stress disorder
dc.subjectpriority journal
dc.subjectpsychopharmacology
dc.subjectrandomized controlled trial
dc.subjectAgoraphobia
dc.subjectCombined Modality Therapy
dc.subjectHumans
dc.subjectPanic Disorder
dc.subjectSerotonin Uptake Inhibitors
dc.titleSelective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: A meta-analysis of randomized controlled trials
dc.typeConference Paper
dc.description.versionConference Paper


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW